Show simple item record

dc.contributor.authorPecori, Biagio
dc.contributor.authorLastoria, Secondo
dc.contributor.authorCaracò, Corradina
dc.contributor.authorCelentani, Marco
dc.contributor.authorTatangelo, Fabiana
dc.contributor.authorAvallone, Antonio
dc.contributor.authorRega, Daniela
dc.contributor.authorDe Palma, Giampaolo
dc.contributor.authorMormile, Maria
dc.contributor.authorBudillon, Alfredo
dc.contributor.authorMuto, Paolo
dc.contributor.authorBianco, Francesco
dc.contributor.authorAloj, Luigi
dc.contributor.authorPetrillo, Antonella
dc.contributor.authorDelrio, Paolo
dc.date.accessioned2018-12-19T00:31:04Z
dc.date.available2018-12-19T00:31:04Z
dc.date.issued2017
dc.identifier.issn1932-6203
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/287178
dc.description.abstractUNLABELLED: Previous studies indicate that FDG PET/CT may predict pathological response in patients undergoing neoadjuvant chemo-radiotherapy for locally advanced rectal cancer (LARC). Aim of the current study is evaluate if pathological response can be similarly predicted in LARC patients after short course radiation therapy alone. METHODS: Thirty-three patients with cT2-3, N0-2, M0 rectal adenocarcinoma treated with hypo fractionated short course neoadjuvant RT (5x5 Gy) with delayed surgery (SCRTDS) were prospectively studied. All patients underwent 3 PET/CT studies at baseline, 10 days from RT end (early), and 53 days from RT end (delayed). Maximal standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) and total lesion glycolysis (TLG) of the primary tumor were measured and recorded at each PET/CT study. We use logistic regression analysis to aggregate different measures of metabolic response to predict the pathological response in the course of SCRTDS. RESULTS: We provide straightforward formulas to classify response and estimate the probability of being a major responder (TRG1-2) or a complete responder (TRG1) for each individual. The formulas are based on the level of TLG at the early PET and on the overall proportional reduction of TLG between baseline and delayed PET studies. CONCLUSIONS: This study demonstrates that in the course of SCRTDS it is possible to estimate the probabilities of pathological tumor responses on the basis of PET/CT with FDG. Our formulas make it possible to assess the risks associated to LARC borne by a patient in the course of SCRTDS. These risk assessments can be balanced against other health risks associated with further treatments and can therefore be used to make informed therapy adjustments during SCRTDS.
dc.format.mediumElectronic-eCollection
dc.languageeng
dc.publisherPublic Library of Science (PLoS)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectHumans
dc.subjectRectal Neoplasms
dc.subjectFluorodeoxyglucose F18
dc.subjectNeoplasm Staging
dc.subjectPrognosis
dc.subjectTreatment Outcome
dc.subjectCombined Modality Therapy
dc.subjectPreoperative Care
dc.subjectRadiotherapy
dc.subjectLogistic Models
dc.subjectROC Curve
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectPositron Emission Tomography Computed Tomography
dc.titleSequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression Analysis.
dc.typeArticle
prism.issueIdentifier1
prism.publicationDate2017
prism.publicationNamePLoS One
prism.startingPagee0169462
prism.volume12
dc.identifier.doi10.17863/CAM.34487
dcterms.dateAccepted2016-12-16
rioxxterms.versionofrecord10.1371/journal.pone.0169462
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-01-06
dc.contributor.orcidAloj, Luigi [0000-0002-7452-4961]
dc.identifier.eissn1932-6203
rioxxterms.typeJournal Article/Review
cam.issuedOnline2017-01-06


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International